Trump’s move to reschedule marijuana has sparked a cannabis stock rally. Despite past losses, ETFs like MJ and MSOS offer a speculative buy-low opportunity.
MSOS portfolio manager calls action an inflection point for the U.S. cannabis industry
Wall Street is currently pivoting toward high-growth biotech plays as federal support accelerates a revolution in alternative medicine.
This cannabis ETF has been a relatively better performer in a mixed market.
MSOS portfolio manager calls executive action a pivotal moment for cannabis policy
Curaleaf stock is up close to 90% in 2025 after President Donald Trump suggested marijuana reclassification could happen within weeks.
Should investors buy, sell, or hold CGC stock after its recent stock resurgence?
With federal marijuana reform gaining traction, the AdvisorShares Pure US Cannabis ETF (MSOS) has surged over 30% in 2025 and stands out as the top-performing fund to capture the sector’s breakout momentum....
When cannabis stocks exploded this week, Tilray Brands (TLRY) wasn’t just along for the ride - it could be setting up for meme stock status.
Cannabis stocks and ETFs soared on Monday after reports that U.S. President Donald Trump is considering reclassifying marijuana to a less restrictive drug category.The potential move would shift marijuana...